AdamJacobSchoenfeldMD

PubMed

• Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.
  Sylvia M Lee, Bernard Doger de Speville, Scott N Gettinger, Simon Hafliger, Sophie Papa, Juan Francisco Rodriguez-Moreno, Friedrich Graf Finckenstein, Rana Fiaz, Melis...> ;Cancer Discovery. 2024 Apr 2
• Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
  Pooja Middha, Rohit Thummalapalli, Michael J Betti, Lydia Yao, Zoe Quandt, Karmugi Balaratnam, Cosmin A Bejan, Eduardo Cardenas, Christina J Falcon, David M Faleck, , ...> ;Nature Communications. 2024 Mar 26
• 1 citations
  Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation.
  Elkrief, A., Waters, N., Smith, N., Dai, A., Slingerland, J., Aleynick, N., Febles, B., Gogia, P., Socci, N., Lumish, M., Giardina, P., Chaft, J., Eng, J., Motzer, R.,...> ;Cancer Immunology Research. 2024 Mar 4
• Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.
  Allison Betof Warner, Omid Hamid, Krishna Komanduri, Rodabe Amaria, Marcus O Butler, John Haanen, Sarah Nikiforow, Igor Puzanov, Amod Sarnaik, Michael R Bishop, Adam J...> ;Journal for Immunotherapy of Cancer. 2024 Feb 29
• Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer.
  Keith A Betts, Sophie Gao, Saurabh Ray, Adam J Schoenfeld> ;Future Oncology. 2024 Apr 1
• 3 citations
  Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer.
  Danish Memon, Adam J Schoenfeld, Darwin Ye, George Fromm, Hira Rizvi, Xiang Zhang, Mohamed Reda Keddar, Divij Mathew, Kyung Jin Yoo, Jingya Qiu, Jayon Lihm, Jayalaksmi...> ;Cancer Cell. 2024 Feb 12
• 1 citations
  Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer.
  Joao V Alessi, Adam Price, Allison L Richards, Biagio Ricciuti, Xinan Wang, Arielle Elkrief, Federica Pecci, Alessandro Di Federico, Malini M Gandhi, Emily S Lebow, Pa...> ;Journal for Immunotherapy of Cancer. 2023 Nov 1
• 3 citations
  Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.
  Vaz, V., Joao V Alessi, Xinan Wang, Arielle Elkrief, Biagio Ricciuti, Yvonne Y Li, Hersh Gupta, Liam F Spurr, Hira Rizvi, Jia Luo, Federica Pecci, Giuseppe Lamberti, G...> ;Journal of Thoracic Oncology. 2023 Nov 1
• 1 citations
  Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and...
  Soo-Ryum Yang, Erika Gedvilaite, Ryan Ptashkin, Jason Chang, John Ziegler, Douglas A Mata, Liliana B Villafania, Khedoudja Nafa, Jaclyn F Hechtman, Ryma Benayed, Ahmet...> ;Journal of Thoracic Oncology. 2024 Mar 1
• Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
  Pooja Middha, Rohit Thummalapalli, Michael J Betti, Lydia Yao, Zoe Quandt, Karmugi Balaratnam, Cosmin A Bejan, Eduardo Cardenas, Christina J Falcon, David M Faleck, , ...> ;Medrxiv. 2023 Sep 13
• 2 citations
  Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
  Arielle Elkrief, Biagio Riccuiti, Joao V Alessi, Teng Fei, Hannah L Kalvin, Jacklynn V Egger, Hira Rizvi, Rohit Thummalapalli, Guiseppe Lamberti, Andrew Plodkowski, Ma...> ;The Oncologist. 2023 Nov 2
• 4 citations
  Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC.
  Joao V Alessi, Biagio Ricciuti, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti, Arielle Elkrief, Scott J Rodig, Emily S Lebow, Jordan E Eicholz,...> ;Nature Communications. 2023 Jul 15
• 3 citations
  Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
  Rohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, Daniel Muldoon, Hira Rizvi, Arielle Elkrief, Jia Luo, Joao V Alessi, Federica Pecci, Giuseppe Lamberti, Ale...> ;Clinical Cancer Research. 2023 Nov 1
• 1 citations
  Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.
  Arielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R Preeshagul, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe L...> ;Journal for Immunotherapy of Cancer. 2023 Jul 1
• 12 citations
  Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
  Vaz, V., Joao V Alessi, Arielle Elkrief, Biagio Ricciuti, Xinan Wang, Alessio Cortellini, Victor R Vaz, Giuseppe Lamberti, Rosa L Frias, Deepti Venkatraman, Claudia A ...> ;Journal of Thoracic Oncology. 2023 Jun 1
• Letter to the Editor: Reply to Zhao, Wu, and Ma.
  Joao V Alessi, Arielle Elkrief, Biagio Ricciuti, Adam J Schoenfeld, Mark M Awad> ;Journal of Thoracic Oncology. 2023 Jun 1
• 5 citations
  Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated With Che...
  Emily S Lebow, Annemarie Shepherd, Jordan E Eichholz, Michael Offin, Daphna Y Gelblum, Abraham J Wu, Charles B Simone 2nd, Adam J Schoenfeld, David R Jones, Andreas Ri...> ;JAMA Network Open. 2023 Jan 3
• 19 citations
  Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
  Vikas, P., Bakouny, Z., Labaki, C., Grover, P., Awosika, J., Gulati, S., Hsu, C., Alimohamed, S., Bashir, B., Berg, S., Bilen, M., Bowles, D., Castellano, C., Desai, A...> ;JAMA Oncology. 2023 Jan 1
• 24 citations
  Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.
  Noura J Choudhury, Antonio Marra, Jane S Y Sui, Jessica Flynn, Soo-Ryum Yang, Christina J Falcon, Pier Selenica, Adam J Schoenfeld, Natasha Rekhtman, Daniel Gomez, Mic...> ;Journal of Thoracic Oncology. 2023 Apr 1
• 80 citations
  Non-viral precision T cell receptor replacement for personalized cell therapy.
  Susan P Foy, Kyle Jacoby, Daniela A Bota, Theresa Hunter, Zheng Pan, Eric Stawiski, Yan Ma, William Lu, Songming Peng, Clifford L Wang, Benjamin Yuen, Olivier Dalmas, ...> ;Nature. 2023 Mar 1
• 57 citations
  Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
  Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Makoto Nishio, Laszlo Urban, Clarisse Audigier-Valette, Lorena Lupinacci, Randeep Sangha, Ad...> ;Journal of Clinical Oncology. 2023 Feb 20
• 34 citations
  Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.
  Amin H Nassar, Elio Adib, Sarah Abou Alaiwi, Talal El Zarif, Stefan Groha, Elie W Akl, Pier Vitale Nuzzo, Tarek H Mouhieddine, Tomin Perea-Chamblee, Kodi Taraszka, Hab...> ;Cancer Cell. 2022 Oct 10
• Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
  Kamrine E Poels, Adam J Schoenfeld, Alex Makhnin, Yosef Tobi, Yuli Wang, Heidie Frisco-Cabanos, Shaon Chakrabarti, Manli Shi, Chelsi Napoli, Thomas O McDonald, Weiwei ...> ;Nature Communications. 2022 Sep 23
• 4 citations
  SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Recepto...
  Hiroki Sato, Daisuke Kubota, Huan Qiao, Achim Jungbluth, Natasha Rekhtman, Adam J Schoenfeld, Helena A Yu, Gregory J Riely, Shinichi Toyooka, Christine M Lovly, Paul P...> ;JCO Precision Oncology. 2022 Aug 1
• 27 citations
  Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS-mutated non-small-cell lung cancer.
  B Ricciuti, J V Alessi, A Elkrief, X Wang, A Cortellini, Y Y Li, V R Vaz, H Gupta, F Pecci, A Barrichello, G Lamberti, T Nguyen, J Lindsay, B Sharma, K Felt, S J Rodig...> ;Annals of Oncology. 2022 Oct 1
• Join now to see all

Journal Articles

• Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung Cancers  
  Helena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology
• Synthesis, Structure, Dynamics, and Selective Methylation of Platinum and Palladium Diphosphametallacyclobutane Complexes  
  Chapp TW, Schoenfeld A, Sanderson MD, Chang C, Glueck DS, Golen J, Moore C, Rheingold A, Organometallics, 2012
• Effects of Linker Length on the Rate and Selectivity of Platinum-Catalyzed Asymmetric Alkylation of the Bis(isitylphosphino)alkanes IsHP(CH2)nPHIs (is = 2,4,6-(i-pr)3C...  
  Chapp TW, Schoenfeld A, Glueck DS, Organometallics, 2010

Abstracts/Posters

• The CNS Germinoma Experience at UCSF from 1980 to 2010
  Schoenfeld A, Molinaro A, Banerjee A, Haas-Kogan D, Mueller S, 3rd International CNS Germ Cell Tumour Symposium, Cambridge, England, 2013

Lectures

• Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers. 
  2019 ASCO Annual Meeting - 6/1/2019